Brookmont Capital Management Amgen Inc Transaction History

Brookmont Capital Management

$187 Million
Q4 2024

A detailed history of Brookmont Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Brookmont Capital Management holds 6,013 shares of AMGN stock, worth $1.69 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares

6,013

Previous 6,143 2.12%

Holding current value

$1.69 Million

Previous $1.98 Million 20.82%

% of portfolio

0.84%

Previous 1.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 16, 2025	SELL	$258.78 - $328.31 $33,641 - $42,680	-130 Reduced 2.12%	6,013 $1.57 Million
Q3 2024 Oct 16, 2024	SELL	$309.38 - $337.38 $55,688 - $60,728	-180 Reduced 2.85%	6,143 $1.98 Million
Q2 2024 Jul 17, 2024	SELL	$262.75 - $319.31 $1.06 Million - $1.28 Million	-4,016 Reduced 38.84%	6,323 $1.98 Million
Q1 2024 Apr 16, 2024	BUY	$268.87 - $324.56 $24,198 - $29,210	90 Added 0.88%	10,339 $2.94 Million
Q4 2023 Jan 18, 2024	SELL	$255.7 - $288.46 $7,159 - $8,076	-28 Reduced 0.27%	10,249 $2.95 Million
Q3 2023 Oct 12, 2023	SELL	$218.65 - $271.46 $12,463 - $15,473	-57 Reduced 0.55%	10,277 $2.76 Million
Q2 2023 Jul 13, 2023	BUY	$214.27 - $253.37 $642 - $760	3 Added 0.03%	10,334 $2.29 Million
Q1 2023 Apr 11, 2023	BUY	$225.79 - $275.2 $6,322 - $7,705	28 Added 0.27%	10,331 $2.5 Million
Q4 2022 Feb 06, 2023	SELL	$229.03 - $291.01 $83,824 - $106,509	-366 Reduced 3.43%	10,303 $2.71 Million
Q3 2022 Oct 12, 2022	BUY	$224.46 - $253.15 $142,307 - $160,497	634 Added 6.32%	10,669 $2.41 Million
Q2 2022 Aug 15, 2022	SELL	$230.71 - $256.74 $83,978 - $93,453	-364 Reduced 3.5%	10,035 $2.44 Million
Q1 2022 May 09, 2022	BUY	$219.27 - $242.57 $15,348 - $16,979	70 Added 0.68%	10,399 $2.52 Million
Q4 2021 Jan 27, 2022	SELL	$198.88 - $227.6 $75,972 - $86,943	-382 Reduced 3.57%	10,329 $2.32 Million
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $33,963 - $39,792	160 Added 1.52%	10,711 $2.28 Million
Q2 2021 Jul 19, 2021	SELL	$233.58 - $259.14 $11,445 - $12,697	-49 Reduced 0.46%	10,551 $2.57 Million
Q1 2021 Apr 15, 2021	SELL	$221.91 - $258.6 $31,511 - $36,721	-142 Reduced 1.32%	10,600 $2.64 Million
Q4 2020 Feb 04, 2021	SELL	$216.38 - $257.67 $171,805 - $204,589	-794 Reduced 6.88%	10,742 $2.47 Million
Q3 2020 Oct 16, 2020	BUY	$234.65 - $260.95 $45,052 - $50,102	192 Added 1.69%	11,536 $2.93 Million
Q2 2020 Jul 23, 2020	SELL	$197.81 - $242.74 $691,741 - $848,861	-3,497 Reduced 23.56%	11,344 $2.68 Million
Q1 2020 Apr 28, 2020	SELL	$182.24 - $241.7 $223,790 - $296,807	-1,228 Reduced 7.64%	14,841 $3.01 Million
Q4 2019 Jan 22, 2020	SELL	$189.21 - $243.2 $328,279 - $421,952	-1,735 Reduced 9.75%	16,069 $3.87 Million
Q3 2019 Nov 07, 2019	BUY	$174.11 - $208.62 $54,670 - $65,506	314 Added 1.8%	17,804 $3.45 Million
Q2 2019 Jul 18, 2019	BUY	$166.7 - $195.41 $19,170 - $22,472	115 Added 0.66%	17,490 $3.22 Million
Q1 2019 Apr 16, 2019	BUY	$180.87 - $203.88 $4,340 - $4,893	24 Added 0.14%	17,375 $3.3 Million
Q4 2018 Feb 12, 2019	SELL	$178.4 - $208.25 $244,229 - $285,094	-1,369 Reduced 7.31%	17,351 $3.38 Million
Q3 2018 Nov 08, 2018	BUY	$185.29 - $208.89 $2,408 - $2,715	13 Added 0.07%	18,720 $3.88 Million
Q2 2018 Jul 19, 2018	BUY	$166.05 - $186.51 $105,109 - $118,060	633 Added 3.5%	18,707 $3.45 Million
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $2.31 Million - $2.7 Million	-13,652 Reduced 43.03%	18,074 $3.08 Million
Q4 2017 Feb 12, 2018	BUY	$168.79 - $188.59 $1.71 Million - $1.92 Million	10,155 Added 47.08%	31,726 $5.52 Million
Q3 2017 Nov 13, 2017	BUY	$167.29 - $191.0 $3.61 Million - $4.12 Million	21,571	21,571 $4.02 Million

Others Institutions Holding AMGN

# of Institutions

3,083

Shares Held

405M

Call Options Held

7.56M

Put Options Held

7.16M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookmont Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookmont Capital Management with notifications on news.

Account

Brookmont Capital Management Amgen Inc Transaction History